{"id":"lw402","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, LW402 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"LW402 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:46.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07370909","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2026-01-30","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":480},{"nctId":"NCT06800157","phase":"PHASE2","title":"Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2023-02-27","conditions":"Arthritis, Rheumatoid","enrollment":72},{"nctId":"NCT07186387","phase":"PHASE2","title":"Study of LW402 in Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","startDate":"2023-05-11","conditions":"Atopic Dermatitis (AD)","enrollment":144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LW402","genericName":"LW402","companyName":"Shanghai Longwood Biopharmaceuticals Co., Ltd.","companyId":"shanghai-longwood-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LW402 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}